Written question asked by George Howarth (Labour) on Friday, 16 February 2024, in the House of Commons. It was due for an answer on Tuesday, 20 February 2024. It was answered by Andrew Stephenson (Conservative) on Wednesday, 21 February 2024 on behalf of the Department of Health and Social Care.
Blood Diseases: Medical Treatments
- Question
-
To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) NICE and (b) NHS England on encouraging the adoption of new treatments for (i) sickle cell disease and (ii) beta-thalassaemia.
- Answer
-
The Department regularly discusses a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), related to patient access to new treatments.
The NICE appraises all new licensed medicines, and its recommendations are developed independently in line with its established methods and processes, on the basis of an assessment of the available evidence, and through extensive engagement with stakeholders. NHS England is legally required to fund treatments recommended in NICE technology appraisal guidance.
Secondary information
- Type
- Written question
- Reference
- 13899
- Session
- 2023-24
- Subjects
- Medical treatments Sickle cell diseases Thalassaemia
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-02-21 16:54:10 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/13899
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/13899
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2023-24/13899